SCHEMBL30765812

SCHEMBL30765812

O=C(O)Cn1c(-c2ccccc2F)ncc(NC2(c3ccc4oc5ccccc5c4c3)CC2)c1=O

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 2/20 0.34
ALDH1A1 P00352 1/20 0.34
LMNA P02545 2/20 0.34
HDAC6 Q9UBN7 2/20 0.33
MAPT P10636 1/20 0.33
THRB P10828 1/20 0.33
NPSR1 Q6W5P4 2/20 0.32
MEN1 O00255 1/20 0.32
POLB P06746 1/20 0.32
GAA P10253 1/20 0.32
HTT P42858 1/20 0.32
KMT2A Q03164 1/20 0.32
RXFP1 Q9HBX9 1/20 0.32
GNRHR P30968 1/20 0.32
GABRP O00591 1/20 0.32
GABRD O14764 1/20 0.32
GABRA1 P14867 1/20 0.32
GABRB1 P18505 1/20 0.32
GABRG2 P18507 1/20 0.32
GABRB3 P28472 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30765703 0.89 ALDH1A1 (0.36) HPGDALDH1A1LMNANPSR1MEN1
SCHEMBL30765690 0.87 GAA (0.40) HPGDALDH1A1LMNAMAPTNPSR1
SCHEMBL30765861 0.82 F3 (0.36) HPGDALDH1A1LMNA
SCHEMBL30766151 0.80 ELANE (0.37) HPGDALDH1A1LMNAHDAC6POLB
SCHEMBL31558526 0.80 LMNA (0.34) HPGDALDH1A1LMNAHDAC6MAPT
SCHEMBL30765964 0.80 GABRP (0.38) HPGDALDH1A1LMNAHDAC6MAPT
SCHEMBL30765536 0.80 LMNA (0.34) HPGDALDH1A1LMNAHDAC6MAPT
SCHEMBL30765662 0.80 LMNA (0.34) HPGDALDH1A1LMNAHDAC6MAPT
SCHEMBL30765745 0.79 ELANE (0.37) HPGDALDH1A1LMNAHDAC6GABRP
SCHEMBL31558470 0.77 LMNA (0.37) HPGDALDH1A1LMNAHDAC6NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4568666-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS Alexion Pharmaceuticals, Inc. (US) 2025-06-18 EP disclosed
CN-119768164-A Pharmaceutical compounds for treating complement-mediated disorders 阿雷克森制药公司 2025-04-04 CN disclosed
WO-2024035686-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMACEUTICALS, INC. (US) 2024-02-15 WO disclosed